Hypoprothrombinemia associated with cefoperazone therapy
- PMID: 3686136
- DOI: 10.1097/00007611-198711000-00007
Hypoprothrombinemia associated with cefoperazone therapy
Abstract
Cefoperazone, a beta-lactam antibiotic with a methylthiotetrazole side chain, has been reported infrequently to cause hypoprothrombinemia and hemorrhage. We retrospectively analyzed the records of 80 patients who had been given this drug for more than 72 hours. Nine patients received vitamin K1 (phytonadione) prophylaxis and had no evidence of hemorrhage. Of the remaining 71 patients, 32 had prothrombin times measured; 14 of them had hypoprothrombinemia. Prothrombin times ranged from 14.8 to 97.3 seconds at a mean of 6.2 days after initiation of therapy. Seven of the 14 patients had clinically significant hemorrhage and five required transfusions. Two patients with clinically evident hemorrhage died during or immediately after cefoperazone therapy. Prothrombin times rapidly returned to normal in all patients treated with phytonadione. We believe hypoprothrombinemia is a more common complication of cefoperazone therapy than is generally acknowledged, and is preventable. Unless clinically contraindicated, we recommend that all patients treated with cefoperazone receive phytonadione prophylaxis.
Similar articles
-
Vitamin K supplementation during prophylactic use of cefoperazone in urologic surgery.Infection. 1992 May-Jun;20(3):146-8. doi: 10.1007/BF01704604. Infection. 1992. PMID: 1644490
-
Hypoprothrombinemia in patients with cancer receiving cefoperazone and mezlocillin.Arch Intern Med. 1986 Jul;146(7):1397-9. Arch Intern Med. 1986. PMID: 3521526 Clinical Trial.
-
Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure.South Med J. 1985 Apr;78(4):488-9. doi: 10.1097/00007611-198504000-00035. South Med J. 1985. PMID: 3872479
-
Determinants of antibiotic-associated hypoprothrombinemia.Pharmacotherapy. 1987;7(3):80-6. doi: 10.1002/j.1875-9114.1987.tb03522.x. Pharmacotherapy. 1987. PMID: 3306622 Review.
-
Potential for bleeding with the new beta-lactam antibiotics.Ann Intern Med. 1986 Dec;105(6):924-31. doi: 10.7326/0003-4819-105-6-924. Ann Intern Med. 1986. PMID: 3535606 Review.
Cited by
-
Cefoperazone-Sulbactam-Induced Coagulopathy in Critically Ill Egyptian Patients: Role of Vitamin K Prophylactic Doses.Hosp Pharm. 2024 Oct;59(5):575-583. doi: 10.1177/00185787241238310. Epub 2024 Mar 13. Hosp Pharm. 2024. PMID: 39318741
-
Cefoperazone/Sulbactam-Induced Abdominal Wall Hematoma and Upper Gastrointestinal Bleeding: A Case Report and Review of the Literature.Drug Saf Case Rep. 2016 Dec;3(1):2. doi: 10.1007/s40800-016-0025-9. Drug Saf Case Rep. 2016. PMID: 27747682 Free PMC article.
-
Cefoperazone Induced Gastrointestinal Bleeding.J Clin Diagn Res. 2016 Aug;10(8):OD10-1. doi: 10.7860/JCDR/2016/19694.8316. Epub 2016 Aug 1. J Clin Diagn Res. 2016. PMID: 27656491 Free PMC article.
-
Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder.Infect Drug Resist. 2023 Sep 21;16:6277-6284. doi: 10.2147/IDR.S429706. eCollection 2023. Infect Drug Resist. 2023. PMID: 37766881 Free PMC article.
-
Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.PLoS One. 2016 Jul 27;11(7):e0158407. doi: 10.1371/journal.pone.0158407. eCollection 2016. PLoS One. 2016. PMID: 27463687 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources